Affiliation:
1. Division of ENT Diseases, Department of Clinical Science Intervention and Technology, Karolinska Institutet Stockholm Sweden
2. Department of Otorhinolaryngology Karolinska University Hospital Stockholm Sweden
3. Medical Unit, Head Neck, Lung and Skin Cancer Karolinska University Hospital Stockholm Sweden
4. Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery Karolinska Institutet and Karolinska University Hospital Stockholm Sweden
5. Department of Otorhinolaryngology – Head and Neck Surgery University of Helsinki and Helsinki University Hospital Helsinki Finland
Abstract
AbstractObjectiveSurvival of patients with advanced laryngeal squamous cell carcinoma (LSCC) remains poor and management protocols warrant further development. We thus investigated treatment and outcome‐related factors for LSCC in Stockholm, Sweden.MethodsIn a retrospective setting, 520 patients with LSCC diagnosed during 2000–2014, were included. Data on stage, treatment, and outcome were correlated with recurrence‐free and overall survival (RFS and OS, respectively).ResultsFive‐year OS for all patients was 65%. Five‐year RFS for T1a, T1b, T2, T3, and T4 glottic LSCC was 90%, 91%, 77%, 47%, and 80%, respectively. The corresponding figures for T1, T2, T3, and T4 supraglottic LSCC were 64%, 66%, 64%, and 86%.ConclusionPatients with a T3 glottic LSCC had unexpectedly poor survival, especially when compared with patients with a T4 tumor. Patients with T4 disease were primarily treated with laryngectomy and postoperative radiotherapy (RT)/chemoradiotherapy (CRT), while most patients with T3 LSCC were treated with RT/CRT.